Evidence map›Paper›PMID 34789731›Full record

ArticleScientific reports2021

SuperSelective primer pairs for sensitive detection of rare somatic mutations.

Fred Russell Kramer, Diana Yaneth Vargas

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Ultrasensitive Detection of Multidrug-ResistantInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fred Russell KramerPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA. fred.kramer@rutgers.edu.
Diana Yaneth VargasPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

Funding

Rapid Analysis of Single T Cell Immunity Signatures in TuberculosisR01AI106036 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BUSHKIN, YURI, GENNARO, MARIA LAURA · 2012 to 2016
$3.8M
Background free amplified single-molecule FISH for in situ and flow cytometric applicationsR01CA227291 · NCI · RBHS-NEW JERSEY MEDICAL SCHOOL · PI TYAGI, SANJAY · 2018 to 2022
$2.8M
NCI NIH HHS R01 CA227291NIAID NIH HHS R01 AI106036NIH HHS R01 CA227291
6 · The paper itself

Abstract

SuperSelective primers, by virtue of their unique design, enable the selective exponential amplification of rare DNA fragments containing somatic mutations in the presence of abundant closely related wild-type DNA fragments. However, when a SuperSelective primer is used in conjunction with a conventional reverse primer, linear amplification of the abundant wild-type fragments occurs, and this may lead to a late arising signal that can be confused with the late arising signal from the rare mutant fragments. We have discovered that the use of a pair of SuperSelective primers, one specific for the target mutation in a plus strand, and the other specific for the same mutation in the complementary minus strand, but both possessing 3'-terminal nucleotides that are complementary to the mutation, significantly suppresses the linear amplification of the related wild-type sequence, and prevents the generation of false mutant sequences due to mis-incorporation by the DNA polymerase. As a consequence, the absence of mutant fragments in a sample does not give rise to a false-positive signal, and the presence of mutant fragments in a sample is clearly distinguishable as a true-positive signal. The use of SuperSelective primer pairs should enhance the sensitivity of multiplex PCR assays that identify and quantitate somatic mutations in liquid biopsies obtained from patients with cancer, thereby enabling the choice of a targeted therapy, the determination of its effectiveness over time, and the substitution of a more appropriate therapy as new mutations arise.

Indexed as

DNA PrimersMutationPolymerase Chain ReactionAllelesDNA Mutational AnalysisGene FrequencyHumansSensitivity and SpecificityDNA Primers

Identifiers

PMID34789731
PMCPMC8599793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.